ngenital cardiac surgeon and Chief Medical Officer of NanoStar Health. "Unfortunately, today this is done by sticking the baby's heel with a scalpel to collect and analyze a blood sample every four to six hours. This method is not only a source of severe trauma, which has recently been linked to adult learning disabilities; but it is also the number one cause of anemia in these sick infants. This medically induced anemia leads to an average of over five blood transfusions per week with standard lab blood testing methods and over three transfusions with newer point-of-care blood testing, with each transfusion introducing additional health risks to these already ailing children," Black said.
"Nanotechnology offers the promise of delivering innovative methods of assessing and treating the health of preemies," said Nihat Okulan, PhD, and Chief Technology Officer of NanoStar Health. "Not only do nanotechnology products meet the size needs of pediatric patients, they also allow us to create new paradigms in clinical methodology including immediate test results utilizing significantly smaller sample sizes. For example, nano-sized devices, which are characterized by their high surface area and low sample
volume, allow for faster response times with the use of lower and safer concentrations of the respective samples," Okulan said.
"The focus of our product development at NanoStar Health is not only assessing the health of premature infants, but doing so in a way that does not further traumatize the infant or require a costly healthcare infrastructure. Therefore, these products will not only benefit the infants born in first-world countries, but in all countries including Africa and Asia where medical technology resources are scarce, but 85 percent of the nearly 13 million preemies are born yearly," said Anita Chambers, PhD, MBA, and Chief Operations Officer of NanoStar Health. "Providing healthcare options to
Page: 1 2 3 4 Related biology technology :1
Copyright©2009 Vocus, Inc.
All rights reserved
. Reportlinker Adds Nanomedicine Report2
. World Nanomedicine Market to Cross $160 Billion by 2015, According to New Report by Global Industry Analysts, Inc.3
. NanoMedicine Summit Returns to Cleveland, September 25-264
. YM BIOSCIENCES ANNOUNCES OFFER FOR CYTOPIA LTD., AN AUSTRALIAN CANCER-FOCUSED DEVELOPMENT COMPANY5
. CEO of Burrill & Company to Speak at BioConference Live Slated for November 17th and 18th 6
. New Oxygen Biotherapeutics, Inc. Investor Presentation Available on Company Website7
. Leading Biotechnology Company Awards Phase III Cardiac Safety Study to iCardiac8
. Global Med Technologies(R) Signs Binding LOI With European Company for Breakthrough Transfusion Safety RFID Product9
. Top 15 Pharmaceutical Company Awards Cardiac Safety Study to iCardiac10
. DNA2.0 Unlocks The Secrets Of Optimized Gene Design: Company Identifies Codon Choice Design Principles for Optimal Protein Expression11
. Gen-Probe to Consolidate Industrial Assets Into New, Independent Company